{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T20:19:14Z","timestamp":1778703554551,"version":"3.51.4"},"reference-count":69,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T00:00:00Z","timestamp":1731974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>VEXAS syndrome is a recently identified autoinflammatory disorder resulting from somatic mutations in the UBA1 gene, leading to a complex spectrum of severe inflammatory and hematologic manifestations. The absence of established treatment guidelines and the variability in clinical presentation make its management particularly challenging. Current therapeutic approaches are often based on limited evidence, and their effectiveness remains inconsistent. This review seeks to consolidate the existing knowledge on therapeutic strategies for VEXAS syndrome, offering a critical evaluation of their efficacy and addressing the gaps in the current literature. As the clinical recognition of VEXAS grows, there is an urgent need to explore more targeted, effective treatments that can address both the inflammatory and hematologic aspects of the disease. By providing a comprehensive analysis of the current therapeutic landscape, this review aims to guide clinicians and researchers toward developing more effective, long-term management strategies for this life-threatening condition.<\/jats:p>","DOI":"10.3390\/jcm13226970","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T11:58:07Z","timestamp":1732017487000},"page":"6970","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["VEXAS Syndrome: A Comprehensive Review of Current Therapeutic Strategies and Emerging Treatments"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3994-8216","authenticated-orcid":false,"given":"Safi","family":"Alqatari","sequence":"first","affiliation":[{"name":"Rheumatology Division, Department of Internal Medicine, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam 31441, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulaziz A.","family":"Alqunais","sequence":"additional","affiliation":[{"name":"College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam 31441, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8353-7393","authenticated-orcid":false,"given":"Shahad M.","family":"Alali","sequence":"additional","affiliation":[{"name":"College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam 31441, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2460-1607","authenticated-orcid":false,"given":"Mohammed A.","family":"Alharbi","sequence":"additional","affiliation":[{"name":"College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam 31441, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9342-7887","authenticated-orcid":false,"given":"Manal","family":"Hasan","sequence":"additional","affiliation":[{"name":"Rheumatology Division, Department of Internal Medicine, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam 31441, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8483-6080","authenticated-orcid":false,"given":"Mohammed D.","family":"Al Shubbar","sequence":"additional","affiliation":[{"name":"College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam 31441, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1056\/NEJMoa2026834","article-title":"Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease","volume":"383","author":"Beck","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/bjd.20805","article-title":"Further characterization of clinical and laboratory features in VEXAS syndrome: Large-scale analysis of a multicentre case series of 116 French patients","volume":"186","author":"Terrier","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jaci.2021.05.014","article-title":"Adult-onset autoinflammation caused by somatic mutations in UBA1: A Dutch case series of patients with VEXAS","volume":"149","author":"Potjewijd","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1016\/j.mayocp.2021.06.006","article-title":"Clinical Heterogeneity of the VEXAS Syndrome","volume":"96","author":"Koster","year":"2021","journal-title":"Mayo Clin. Proc."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1053\/j.seminhematol.2021.10.006","article-title":"Thrombotic manifestations of VEXAS syndrome","volume":"58","author":"Groarke","year":"2021","journal-title":"Semin. Hematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1182\/blood.2022016985","article-title":"Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis","volume":"140","author":"Ferrada","year":"2022","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1001\/jamadermatol.2024.1657","article-title":"Skin Manifestations of VEXAS Syndrome and Associated Genotypes","volume":"160","author":"Tan","year":"2024","journal-title":"JAMA Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.tcb.2013.12.003","article-title":"Perilous journey: A tour of the ubiquitin\u2013proteasome system","volume":"24","author":"Kleiger","year":"2014","journal-title":"Trends Cell Biol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Aksentijevich, I., and Zhou, Q. (2017). NF-\u03baB Pathway in Autoinflammatory Diseases: Dysregulation of Protein Modifications by Ubiquitin Defines a New Category of Autoinflammatory Diseases. Front. Immunol., 8.","DOI":"10.3389\/fimmu.2017.00399"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e0174","DOI":"10.1199\/tab.0174","article-title":"The Ubiquitination Machinery of the Ubiquitin System","volume":"12","author":"Callis","year":"2014","journal-title":"Arab. Book"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1136\/ard-2023-224460","article-title":"Spanish cohort of VEXAS syndrome: Clinical manifestations, outcome of treatments and novel evidences about UBA1 mosaicism","volume":"82","author":"Mascaro","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/art.41992","article-title":"VEXAS Syndrome: A Case Series From a Single-Center Cohort of Italian Patients with Vasculitis","volume":"74","author":"Muratore","year":"2022","journal-title":"Arthritis Rheumatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1182\/bloodadvances.2021004976","article-title":"Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1","volume":"5","author":"Obiorah","year":"2021","journal-title":"Blood Adv."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1136\/annrheumdis-2021-220089","article-title":"Pathogenic UBA1 variants associated with VEXAS syndrome in Japanese patients with relapsing polychondritis","volume":"80","author":"Tsuchida","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e435","DOI":"10.1093\/rheumatology\/keab524","article-title":"Atypical splice-site mutations causing VEXAS syndrome","volume":"60","author":"Duroyon","year":"2021","journal-title":"Rheumatology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1182\/blood.2020010286","article-title":"Novel somatic mutations in UBA1 as a cause of VEXAS syndrome","volume":"137","author":"Poulter","year":"2021","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1182\/blood.2020010177","article-title":"Therapeutic options in VEXAS syndrome: Insights from a retrospective series","volume":"137","author":"Bourbon","year":"2021","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/bjh.17893","article-title":"Azacitidine for patients with Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: Data from the French VEXAS registry","volume":"196","author":"Comont","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/s41467-024-44811-4","article-title":"VEXAS syndrome is characterized by inflammasome activation and monocyte dysregulation","volume":"15","author":"Kosmider","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"rkae065","DOI":"10.1093\/rap\/rkae065","article-title":"Targeting enhanced cell death represents a potential therapeutic strategy for VEXAS syndrome","volume":"8","author":"Adachi","year":"2024","journal-title":"Rheumatol. Adv. Pract."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"101160","DOI":"10.1016\/j.xcrm.2023.101160","article-title":"Early activation of inflammatory pathways in UBA1-mutated hematopoietic stem and progenitor cells in VEXAS","volume":"4","author":"Wu","year":"2023","journal-title":"Cell Rep. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"170","DOI":"10.5582\/irdr.2023.01020","article-title":"VEXAS syndrome: Current clinical, diagnostic and treatment approaches","volume":"12","author":"Kobak","year":"2023","journal-title":"IRDR"},{"key":"ref_23","unstructured":"Goring, S., and Horton, J. (2024, July 09). Treatment Options for VEXAS Syndrome: Rapid Review, Available online: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK602672\/."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1053\/j.seminhematol.2021.09.001","article-title":"Toward a pathophysiology inspired treatment of VEXAS syndrome","volume":"58","author":"Heiblig","year":"2021","journal-title":"Semin. Hematol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Tozaki, N., Tawada, C., Niwa, H., Mizutani, Y., Shu, E., Kawase, A., Miwa, Y., Ohnishi, H., Sasai, H., and Miyako, K. (2022). A case of VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) with decreased oxidative stress levels after oral prednisone and tocilizumab treatment. Front. Med., 9.","DOI":"10.3389\/fmed.2022.1046820"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1007\/s10875-021-01070-y","article-title":"A Case of VEXAS Syndrome Complicated by Hemophagocytic Lymphohistiocytosis","volume":"41","author":"Grey","year":"2021","journal-title":"J. Clin. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jdcr.2021.06.010","article-title":"Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome\u2014Clinical presentation of a newly described somatic, autoinflammatory syndrome","volume":"14","author":"Alhomida","year":"2021","journal-title":"JAAD Case Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1055\/s-0043-1770958","article-title":"VEXAS Syndrome\u2014Review","volume":"10","author":"Zhang","year":"2023","journal-title":"Glob. Med. Genet."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e174","DOI":"10.1093\/rheumatology\/keac054","article-title":"VEXAS syndrome: Favourable clinical and partial haematological responses to subcutaneous abatacept therapy with 30-month follow-up","volume":"61","author":"Pathmanathan","year":"2022","journal-title":"Rheumatology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1093\/rheumatology\/kead240","article-title":"How to treat VEXAS syndrome: A systematic review on effectiveness and safety of current treatment strategies","volume":"62","author":"Boyadzhieva","year":"2023","journal-title":"Rheumatology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/blood.2022016642","article-title":"Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: A retrospective multicenter study","volume":"140","author":"Heiblig","year":"2022","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/S0140-6736(23)02649-1","article-title":"Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): A randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial","volume":"403","author":"Cope","year":"2024","journal-title":"Lancet"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Johansen, M.M., El Fassi, D., Nielsen, C.T.H., Krintel, S.B., Graudal, N., and Hansen, J.W. (2023). Treatment experiences with focus on IL-6R inhibition in patients with VEXAS syndrome and a case of remission with azacytidine treatment. Rheumatology, kead697.","DOI":"10.1093\/rheumatology\/kead697"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Kunishita, Y., Kirino, Y., Tsuchida, N., Maeda, A., Sato, Y., Takase-Minegishi, K., Yoshimi, R., and Nakajima, H. (2022). Case Report: Tocilizumab Treatment for VEXAS Syndrome with Relapsing Polychondritis: A Single-Center, 1-Year Longitudinal Observational Study in Japan. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.901063"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jdcr.2022.02.022","article-title":"Tocilizumab for treatment of cutaneous and systemic manifestations of vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome without myelodysplastic syndrome","volume":"23","author":"Goyal","year":"2022","journal-title":"JAAD Case Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"734","DOI":"10.3899\/jrheum.2022-0226","article-title":"VEXAS Syndrome: Clinical Case Series from a Canadian Cohort","volume":"51","author":"Williams","year":"2024","journal-title":"J. Rheumatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1182\/bloodadvances.2021004749","article-title":"Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: A 2-center experience","volume":"6","author":"Diarra","year":"2022","journal-title":"Blood Adv."},{"key":"ref_38","first-page":"e12","article-title":"Case report: Up-front allogeneic stem cell transplantation in a patient with the VEXAS syndrome","volume":"199","author":"Heijstek","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"E28","DOI":"10.1002\/ajh.26786","article-title":"Reduced intensity conditioning allogeneic hematopoietic stem cell transplantation in VEXAS syndrome: Data from a prospective series of patients","volume":"98","author":"Mangaonkar","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1182\/bloodadvances.2023012478","article-title":"Allogeneic hematopoietic cell transplantation for VEXAS syndrome: Results of a multicenter study of the EBMT","volume":"8","author":"Gurnari","year":"2024","journal-title":"Blood Adv."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e934","DOI":"10.1097\/HS9.0000000000000934","article-title":"Recovery of Bone Marrow Function in VEXAS Syndrome-potential Role for Romiplostim","volume":"7","author":"Cull","year":"2023","journal-title":"HemaSphere"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.2165\/11202840-000000000-00000","article-title":"Azacitidine: A Review of its Use in Higher-Risk Myelodysplastic Syndromes\/Acute Myeloid Leukaemia","volume":"69","author":"Keating","year":"2009","journal-title":"Drugs"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.leukres.2016.02.005","article-title":"Efficacy of Azacitidine in autoimmune and inflammatory disorders associated with myelodysplastic syndromes and chronic myelomonocytic leukemia","volume":"43","author":"Fraison","year":"2016","journal-title":"Leuk. Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e661","DOI":"10.1097\/HS9.0000000000000661","article-title":"Azacytidine Treatment for VEXAS Syndrome","volume":"5","author":"Raaijmakers","year":"2021","journal-title":"HemaSphere"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.3324\/haematol.2024.285519","article-title":"De-escalation of corticosteroids and clonal remission in UBA1 mutation-driven VEXAS syndrome with 5-azacytidine","volume":"109","author":"Trikha","year":"2024","journal-title":"Haematologica"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.1002\/hem3.129","article-title":"Long-term genetic and clinical remissions after cessation of azacitidine treatment in patients with VEXAS syndrome","volume":"8","author":"Aalbers","year":"2024","journal-title":"HemaSphere"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1093\/rheumatology\/keab866","article-title":"Successful treatment with azacitidine in VEXAS syndrome with prominent myofasciitis","volume":"61","author":"Cordts","year":"2022","journal-title":"Rheumatology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s12185-023-03532-y","article-title":"Successful azacitidine therapy for myelodysplastic syndrome associated with VEXAS syndrome","volume":"117","author":"Kataoka","year":"2023","journal-title":"Int. J. Hematol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s00277-023-05611-w","article-title":"VEXAS syndrome: Complete molecular remission after hypomethylating therapy","volume":"103","author":"Sockel","year":"2024","journal-title":"Ann. Hematol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1038\/s41375-022-01698-8","article-title":"A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune\/inflammatory disorders and VEXAS syndrome associated with MDS and CMML","volume":"36","author":"Mekinian","year":"2022","journal-title":"Leukemia"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Pereira Da Costa, R., Sapinho, G., Bandeira, M., Infante, J., Marques, T., Mimoso Santos, C., Forjaz De Lacerda, J., Fonseca, J.E., and Romeu, J.C. (2024). Case report: VEXAS syndrome: An atypical indolent presentation as sacroiliitis with molecular response to azacitidine. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1403808"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1016\/S0140-6736(19)33008-9","article-title":"Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): A randomised, phase 3, non-inferiority trial","volume":"394","author":"Poeschel","year":"2019","journal-title":"Lancet"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/mrcr\/rxad041","article-title":"Long-term remission of VEXAS syndrome achieved by a single course of CHOP therapy: A case report","volume":"8","author":"Miyoshi","year":"2023","journal-title":"Mod. Rheumatol. Case Rep."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Sun, Y.-Q., Han, T.-T., Wang, Y., Yan, C.-H., Wang, F.-R., Wang, Z.-D., Kong, J., Chen, Y.-H., Chen, H., and Han, W. (2021). Haploidentical Stem Cell Transplantation with a Novel Conditioning Regimen in Older Patients: A Prospective Single-Arm Phase 2 Study. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.639502"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Bellman, P., Gonzalez-Lugo, J.D., Shahzad, M., Amin, M.K., Khalid, M.F., Suleman, N., Ahmed, N., Singh, A.K., Yacoub, A., and Zhang, D. (2024). Successful treatment with fludarabine and cyclophosphamide in a VEXAS syndrome patient with associated myelodysplastic syndrome: A case report and systematic review. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1383730"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Velikova, T., Sekulovski, M., Bogdanova, S., Vasilev, G., Peshevska-Sekulovska, M., Miteva, D., and Georgiev, T. (2023). Intravenous Immunoglobulins as Immunomodulators in Autoimmune Diseases and Reproductive Medicine. Antibodies, 12.","DOI":"10.3390\/antib12010020"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e314","DOI":"10.1093\/rheumatology\/keab211","article-title":"VEXAS syndrome in a patient with previous spondyloarthritis with a favourable response to intravenous immunoglobulin and anti-IL17 therapy","volume":"60","author":"Magnol","year":"2021","journal-title":"Rheumatology"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Staels, F., Betrains, A., Woei-A-Jin, F.J.S.H., Boeckx, N., Beckers, M., Bervoets, A., Willemsen, M., Neerinckx, B., Humblet-Baron, S., and Blockmans, D.E. (2021). Case Report: VEXAS Syndrome: From Mild Symptoms to Life-Threatening Macrophage Activation Syndrome. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.678927"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.jaci.2023.02.017","article-title":"Autoimmune manifestations in VEXAS: Opportunities for integration and pitfalls to interpretation","volume":"151","author":"Bruno","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"94","DOI":"10.23822\/EurAnnACI.1764-1489.30","article-title":"Successful rapid subcutaneous desensitization to anakinra in a case with a severe immediate-type hypersensitivity reaction","volume":"50","author":"YIlmaz","year":"2017","journal-title":"Eur. Ann. Allergy Clin. Immunol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1002\/art.42101","article-title":"Successful use of cyclosporin A and interleukin-1 blocker combination therapy in VEXAS syndrome: A single-center case series","volume":"74","author":"Campochiaro","year":"2022","journal-title":"Arthritis Rheumatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"107584","DOI":"10.1016\/j.leukres.2024.107584","article-title":"Association between myeloid disorders and adult onset-inflammatory syndromes, successful treatment with JAK-inhibitors: Case series and literature review","volume":"146","author":"Mishra","year":"2024","journal-title":"Leuk. Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1136\/ard-2024-225640","article-title":"Efficacy and safety of targeted therapies in VEXAS syndrome: Retrospective study from the FRENVEX","volume":"83","author":"Hadjadj","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1111\/1756-185X.14785","article-title":"Tofacitinib as a biologic response modifier in VEXAS syndrome: A case series","volume":"26","author":"Salehi","year":"2023","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/imj.15742","article-title":"VEXAS syndrome: Lessons learnt from an early Australian case series","volume":"52","author":"Islam","year":"2022","journal-title":"Intern. Med. J."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Vu, K.T., Wolfe, R.M., Lambird, J.E., and Maracaja, D.L.V. (2023). A case of VEXAS syndrome presenting with unusual bone marrow granulomas: A diagnostic dilemma. BMC Rheumatol., 7.","DOI":"10.1186\/s41927-023-00343-w"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.reuma.2023.10.006","article-title":"VEXAS syndrome: Clinical manifestations, diagnosis, and treatment","volume":"20","author":"Ferrada","year":"2024","journal-title":"Reumatol. Cl\u00ednica"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e15050","DOI":"10.1111\/exd.15050","article-title":"VEXAS syndrome: A review of cutaneous findings and treatments in an emerging autoinflammatory disease","volume":"33","author":"Saad","year":"2024","journal-title":"Exp. Dermatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/ddg.14933","article-title":"Vexas syndrome successfully treated with canakinumab","volume":"21","year":"2023","journal-title":"J. Dtsch. Dermatol. Gesellschaf."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/22\/6970\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:35:22Z","timestamp":1760114122000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/22\/6970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,19]]},"references-count":69,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["jcm13226970"],"URL":"https:\/\/doi.org\/10.3390\/jcm13226970","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,19]]}}}